









Markets
/
Stocks
/
nasdaq-alny
/

Alnylam Pharmaceuticals Inc

ALNY

449.560USD

-32.030-6.65%

Close 10/30, 16:00（ET）Quotes delayed by 15 min

58.88BMarket Cap

LossP/E TTM



Alnylam Pharmaceuticals Inc

449.560

-32.030-6.65%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Alnylam Pharmaceuticals Inc

Currency: USD Updated: 2025-10-29

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Alnylam Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

15 / 160

Overall Ranking

48 / 4623

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 30 analysts

Buy

Current Rating

457.164

Target Price

-3.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Alnylam Pharmaceuticals Inc Highlights

StrengthsRisks

Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 116.72% year-on-year.

Undervalued

The company’s latest PE is -194.60, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 129.94M shares, decreasing 2.49% quarter-over-quarter.

Held by Baillie Gifford

Star Investor Baillie Gifford holds 3.03M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.39.

Financial Health

Currency: USD Updated: 2025-10-29

The company's current financial score is 7.68, which is lower than the Pharmaceuticals industry's average of 7.76. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 773.69M, representing a year-over-year increase of 17.26%, while its net profit experienced a year-over-year increase of 292.43%.

Score

Industry at a Glance

Previous score

7.68

Change



Financials

6.08

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.69

Key Metrics

Free cash flow

No Data

Alnylam Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2025-10-29

The company’s current valuation score is 7.42, which is higher than the Pharmaceuticals industry's average of 7.22. Its current P/E ratio is -194.60, which is -100.00% below the recent high of 0.00 and -162.95% above the recent low of -511.69.

Score

Industry at a Glance

Previous score

7.42

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 15/160

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-29

The company’s current earnings forecast score is 7.93, which is higher than the Pharmaceuticals industry's average of 7.79. The average price target for Alnylam Pharmaceuticals Inc is 474.00, with a high of 570.00 and a low of 236.00.

Score

Industry at a Glance

Previous score

7.93

Change

Support & Resistance

No Data

Analyst Rating

Based on 30 analysts

Buy

Current Rating

460.779

Target Price

-4.32%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Alnylam Pharmaceuticals Inc

ALNY

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

AbbVie Inc

ABBV

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-29

The company’s current price momentum score is 9.06, which is higher than the Pharmaceuticals industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 502.70 and the support level at 453.33, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.79

Change

0.27

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(5)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-3.528

Neutral

RSI(14)

42.577

Neutral

STOCH(KDJ)(9,3,3)

38.359

Sell

ATR(14)

19.112

Low Volatility

CCI(14)

-171.354

Sell

Williams %R

77.899

Sell

TRIX(12,20)

0.158

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

469.814

Sell

MA10

472.486

Sell

MA20

467.327

Sell

MA50

460.598

Sell

MA100

407.097

Buy

MA200

334.953

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-29

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 5.79. The latest institutional shareholding proportion is 99.13%, representing a quarter-over-quarter decrease of 1.40%. The largest institutional shareholder is The Vanguard, holding a total of 13.24M shares, representing 10.10% of shares outstanding, with 3.00% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Capital World Investors

16.81M

+0.33%

Fidelity Management & Research Company LLC

15.05M

+2.92%

The Vanguard Group, Inc.

Star Investors

13.24M

+1.83%

Capital Research Global Investors

7.19M

+0.52%

BlackRock Institutional Trust Company, N.A.

6.53M

-2.96%

Regeneron Pharmaceuticals Inc

4.44M

T. Rowe Price Investment Management, Inc.

4.28M

-3.10%

Dodge & Cox

Star Investors

3.20M

-4.61%

State Street Investment Management (US)

3.17M

-5.75%

T. Rowe Price Associates, Inc.

Star Investors

3.05M

-10.55%

Risk Assessment

Currency: USD Updated: 2025-10-29

The company’s current risk assessment score is 8.67, which is higher than the Pharmaceuticals industry's average of 5.13. The company's beta value is 0.30. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.